Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This Chinese herbal preparation is a combination of *Radix Polygoni Multiflori* (He Shou Wu) and *Radix Salviae Miltiorrhizae* (Danshen). It has been investigated by researchers at Monash University for its potential to mitigate cardiovascular disease risk, particularly in patients with hyperlipidemia. The preparation works through a multi-target approach: *Radix Polygoni Multiflori* contains stilbene glycosides like 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside (TSG), which inhibits HMG-CoA reductase and acts as a potent antioxidant. *Radix Salviae Miltiorrhizae* contributes tanshinones and salvianolic acids, which inhibit platelet aggregation (via COX-1 inhibition) and improve microcirculation. Clinical trials have focused on the preparation's ability to improve lipid profiles, reduce oxidative stress markers, and enhance vascular function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on radix polygoni multiflori + radix salviae miltiorrhizae.